U.S FDA has accepted IND application for COMP360 in PTSD, enabling the initiation of a Phase 2b/3 (COMP202) clinical trial in patients living with PTSD.

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic collaborati ...

Compass Pathways has entered its seventh U.S. strategic collaboration with Radial Health. Radial Health operates in five ...

The company is also advancing commercial preparations for COMP360 in treatment-resistant depression (TRD), aiming to be launch-ready by the end of the year if approved. Compass recently held a ...

Shares of Compass Pathways Plc (NASDAQ:CMPS) rose about 3% in premarket trading on Wednesday after the company said the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND ...

Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trial Compass continues to ...

Kallyope, a late-stage biotechnology company focused on developing innovative migraine and metabolic disease therapies for health challenges faced by hundreds of millions of people globally, announced ...

PSQ Holdings, Inc. ("PublicSquare" or the "Company"), today announced updates to its Board and executive leadership structure intended to delineate board oversight, enhance operational focus, and ...

CMPS has benefited from positive phase 3 trial results and positive political developments since my last article. Click here ...

The chain faced shortfalls in foot traffic due to significant changes to the workforce and consumption patterns in the ...

We are thrilled to welcome Arjun and Cyndi to the Compass team. They are highly accomplished leaders with decades of commercial and clinical development experience,” said Thomas Schuetz, MD, PhD, CEO ...